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Abstract
Background: Nolz1 is a zinc finger transcription factor whose expression is enriched in the lateral ganglionic
eminence (LGE), although its function is still unknown.
Results: Here we analyze the role of Nolz1 during LGE development. We show that Nolz1 expression is high in
proliferating neural progenitor cells (NPCs) of the LGE subventricular zone. In addition, low levels of Nolz1 are
detected in the mantle zone, as well as in the adult striatum. Similarly, Nolz1 is highly expressed in proliferating
LGE-derived NPC cultures, but its levels rapidly decrease upon cell differentiation, pointing to a role of Nolz1 in the
control of NPC proliferation and/or differentiation. In agreement with this hypothesis, we find that Nolz1 over-
expression promotes cell cycle exit of NPCs in neurosphere cultures and negatively regulates proliferation in
telencephalic organotypic cultures. Within LGE primary cultures, Nolz1 over-expression promotes the acquisition of
a neuronal phenotype, since it increases the number of b-III tubulin (Tuj1)- and microtubule-associated protein
(MAP)2-positive neurons, and inhibits astrocyte generation and/or differentiation. Retinoic acid (RA) is one of the
most important morphogens involved in striatal neurogenesis, and regulates Nolz1 expression in different systems.
Here we show that Nolz1 also responds to this morphogen in E12.5 LGE-derived cell cultures. However, Nolz1
expression is not regulated by RA in E14.5 LGE-derived cell cultures, nor is it affected during LGE development in
mouse models that present decreased RA levels. Interestingly, we find that Gsx2, which is necessary for normal RA
signaling during LGE development, is also required for Nolz1 expression, which is lost in Gsx2 knockout mice. These
findings suggest that Nolz1 might act downstream of Gsx2 to regulate RA-induced neurogenesis. Keeping with this
hypothesis, we show that Nolz1 induces the selective expression of the RA receptor (RAR)b without altering RARa
or RARg. In addition, Nozl1 over-expression increases RA signaling since it stimulates the RA response element. This
RA signaling is essential for Nolz1-induced neurogenesis, which is impaired in a RA-free environment or in the
presence of a RAR inverse agonist. It has been proposed that Drosophila Gsx2 and Nolz1 homologues could
cooperate with the transcriptional co-repressors Groucho-TLE to regulate cell proliferation. In agreement with this
view, we show that Nolz1 could act in collaboration with TLE-4, as they are expressed at the same time in NPC
cultures and during mouse development.
Conclusions: Nolz1 promotes RA signaling in the LGE, contributing to the striatal neurogenesis during
development.
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Background
During the first stages of striatal development, neurons
arise from the ventricular zone (VZ), which is mainly
composed of neuroepithelial cells [1,2]. Around embryo-
nic day (E)11.5, these cells divide asymmetrically; giving
rise to radial glial cells and neural progenitor cells
(NPCs). Radial glial cells have extensions that contact
with the ventricular lumen and with more differentiated
inner zones of the developing striatum, but their cell
bodies remain in the VZ [3-5]. In contrast, NPCs leave
the VZ to proliferate and generate the so-called subven-
tricular zone (SVZ). Within the dorsal telencephalon,
the SVZ is a thin layer of cells, mainly formed of NPCs
[4,6]. However, in the ventral telencephalon, it becomes
a prominent structure that has been shown to be the
main source of striatal neurons and glia. Striatal project-
ing neurons are born in the SVZ of the lateral ganglio-
nic eminence (LGE) whereas the medial ganglionic
eminence will give rise to cortical and striatal
interneurons.
Retinoic acid (RA) is one of the morphogens that par-
ticipates in the specification and differentiation of the
intermediate position of the LGE in the telencephalon
[7]. However, RA sources during telencephalon develop-
ment are still unclear. Three different retinaldehyde
dehydrogenases (Raldhs), the limiting enzymes for RA
synthesis, have been described in the central nervous
system. Two of them, Raldh2 and Raldh3, are expressed
in the otic vesicles and frontonasal ectoderm, respec-
tively, as early as E8.5 [8-10]. Thus, it is unlikely that
RA from these sources could reach the intermediate tel-
encephalon. Around E12.5, Raldh3 expression appears
in the LGE, providing the first known source of RA
in the striatum [9,11]. During this period, the expression
of the RA receptors (RARs) RARa and RARb is high in
the ventral telencephalon and it has been shown that
RARb stimulation mediates gene regulation in the devel-
oping telencephalon, particularly on striatal neuronal
populations [12] where 95% of neurons are GABAergic
[13]. In addition, RA increases the number of GABAer-
gic neurons in differentiating mouse embryonic stem
cells through the regulation of RARb [14,15]. Some
transcription factors are of great importance for RA sig-
naling in the LGE. Among these is the homeobox tran-
scription factor Gsx2, which is essential for correct
striatal development [16,17] and for Raldh3 expression.
Raldh3 levels are severely reduced or lost in mice defi-
cient for Gsx2 or Gsx1 and Gsx2 [18].
To exert its effect during development, RA binds spe-
cific RARs and, thereafter, regulates the expression of
some transcription factors that contain a RA response
element (RARE) in their promoter. One of these tran-
scription factors is Nolz1, which is induced by RA in
the PC12 neural cell line and during developing chick
spinal cord [19,20]. Nolz1 is a member of the NocA-
Elbow (elB)-Tlp (NET) family of transcription factors,
which are involved in patterning and differentiation dur-
ing development in all studied species [21-24]. In zebra-
fish, two members of the NET family have been
identified, nlz1 and nlz2, and both have been described
to be essential for boundary formation in the rombence-
phalon [23,24]. Nlz2 is also expressed in more anterior
structures, including the telencephalic vesicles, where it
is supposed to play similar roles in regionalization [25].
A Nlz2 homolog in rodents was called Nolz1 (also
known as Zfp503), which is expressed during nervous
system development in several regions, including the
hypothalamus and spinal cord. However, its highest
expression is localized in the ventral LGE (vLGE)
[19,26]. Of note, Nolz1 is totally absent in close telence-
phalic structures such as the medial ganglionic emi-
nence and the pallidum, including the dorsal LGE
(dLGE) [19], suggesting a highly specific striatal func-
tion. However, this family of transcription factors cannot
directly interact with DNA, indicating that they need to
interact with other transcription factors. In Drosophila,
it has been shown that elbow B (elB) interacts with
Groucho (Gro) proteins, forming large complexes of
proteins that act as transcriptional co-repressors [27].
Despite its characterized pattern of expression, the
function of Nolz1 during telencephalic development has
not been analyzed yet. Here we studied the role of
Nolz1 during vLGE development and the relationship
between Nolz1 and the RA pathway within the LGE.
Our results show that Nolz1 induces cell cycle exit and
promotes neuronal differentiation. In addition, we also
demonstrate that Nolz1 expression is temporarily regu-
lated by RA during early striatal development. Finally,
we show that Nolz1 contributes to neuronal differentia-
tion through the increase of RA signaling.
Results
Nolz1 expression is regulated during striatal development
In order to analyze whether the temporal expression
pattern of Nolz1 protein resembles that of Nolz1
mRNA, a polyclonal antibody was raised against 12
amino acids of the amino terminus of the Nolz1 protein
sequence (Figure 1A). Western blotting of NPC lysates
showed that the antibody recognizes a unique specific
band when compared to the pre-serum blotted mem-
brane (Figure 1B). In addition, dot blot analyses demon-
strated the specificity of the serum (Figure 1C), which
could be blocked by the competitive incubation of the
antibody with the Nolz1 peptide (Figure 1D). Using this
Nolz1 polyclonal antibody, we performed western blot
analysis in striatal samples from E14.5, E18.5, postnatal
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day (P)3 and adult mice. Our results showed that Nolz1
levels are high at embryonic stages, being down-
regulated postnatally (Figure 2A). Within the adult, low
levels of Nolz1 protein remained in the striatum while
no expression was detected in the subependymal zone
(Figure 2A). In situ hybridization for Nolz1 showed high
levels of mRNA in the SVZ of the vLGE at E14.5 (Figure
2B). No signal was detected in the dLGE (Figure 2B),
which gives rise to olfactory bulb interneurons during
development [28]. Low levels of Nolz1 mRNA were also
detected in the mantle zone (MZ; Figure 2B,D), where it
partially co-localized with Tuj1-positive neurons (Figure
2D,E). In the adult brain, similar to the protein results,
Nolz1 mRNA was not detected in the subependymal
zone, although faint expression could still be detected in
the striatum by in situ hybridization (Figure 2C).
Nolz1 regulates NPC homeostasis in the LGE
The high levels of Nolz1 expression in the SVZ of the
vLGE suggest it has a role in the regulation of NPC
homeostasis. Thus, to analyze the function of Nolz1 in
NPCs, we generated neurospheres from the LGE of
E14.5 mice. Nolz1 expression was analyzed in proliferat-
ing cells and at 3 and 6 days in vitro (DIV) after the
induction of neurosphere differentiation (Figure 3A,B).
We observed that Nolz1 expression levels were high in
non-differentiated cells, while its expression decreased
during the differentiation process for both mRNA
(Figure 3A) and protein (Figure 3B). These results were
coincident with the expression pattern of Nolz1 in vivo,
which mainly corresponded to the NPC-containing SVZ
(Figure 2B).
We next analyzed whether Nolz1 regulates NPC prolif-
eration. Over-expression of human Nolz (hNolz) in NPCs
led to high hNolz mRNA levels but a significant decrease
in endogenous mouse Nolz1 expression (Figure 4A),
suggesting tight regulation of mouse Nolz1 levels. When
we analyzed Nolz protein levels with a Nolz1 antibody
that detects mouse and human isoforms, we found a net
increase in Nolz protein levels with respect to control
transfected cells (Figure 4B). hNolz-over-expressing neu-
rospheres showed a 19.5% reduction in the number of
proliferating bromodeoxyuridine (BrdU)-positive NPCs
with respect to control transfected cells (Figure 4D,E).
Double immunocytochemistry showed that most, but not
all, of the hNolz-over-expressing cells were negative for
BrdU (Figure 4D). To verify that the reduction in BrdU-
positive cells was due to cell cycle exit and not to varia-
tions in its duration, we measured the cell cycle time of
transfected NPCs as described elsewhere [29] and did not
find any difference between control and hNolz-over-
expressing neurospheres (DsRED, 25.29 h; hNolz-DsRED,
24.88 h). In addition, we analyzed the index of cell cycle
exit as described previously by Chenn and Walsh [30].
This demonstrated that hNolz over-expression produces a
significant increase of 162% in the cell cycle exit index
(Figure 4G). Since the reduction in the number of BrdU-
positive NPCs may also be due to cell death, we also
counted the number of apoptotic nuclei of hNolz-over-
expressing NPCs with respect to control enhanced green
fluorescent protein (EGFP)-transfected NPCs. No cell
death was observed in any condition (data not shown).
In addition, the effect of Nolz1 silencing was also ana-
lyzed by using a cocktail of three different Nolz1 small
interfering RNAs (siRNAs) at a concentration of 2 μM,
which led to 60% inhibition of Nolz1 mRNA (data not
shown) and 82% inhibition of Nolz1 protein expression
2 DIV after transfection (Figure 4C). As expected, trans-
fection of Nolz1 siRNA increased the number of BrdU-
positive NPCs (by 18.5%) in the neurosphere cultures
with respect to scrambled negative siRNA control trans-
fection (Figure 4E). Taken together, these findings
demonstrate that deregulation of Nolz1 altered the pro-
liferating capacity of NPCs, suggesting that Nolz1
Figure 1 Characterization of the anti-Nolz1 polyclonal
antibody. (A) Representation of Nolz1 showing the peptide against
which the polyclonal antibody was raised. FKPY, Groucho consensus
binding site; ZF, zinc-finger domain. (B) Western blots of NPC
protein extracts, showing endogenous Nolz1 expression.
Membranes were incubated with a rabbit serum obtained before
(pre-serum; PS) or after (Nolz1) immunization. The specific band
corresponding to Nolz1 (63 kDa; arrow) is visible only with the anti-
Nolz1 antibody. (C) Dot-blot against Nolz1 pure peptide (upper
drop; open arrowheads) or Keyhole limpet hemocyanin (KLH)-
conjugated Nolz1 peptide (lower drop; closed arrowheads)
incubated with rabbit serum before (pre-serum; PS) and after
(Nolz1) immunization, showing Nolz1 antibody specificity. (D) Nolz1
pure peptide dots immuno-blotted with the anti-Nolz1 polyclonal
antibody pre-incubated in the presence (Peptide) or in the absence
(Control) of Nolz1 peptide.
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Figure 2 The pattern of Nolz1 protein expression resembles that of Nolz1 mRNA in the LGE. (A) Western blot analysis of striatal samples
from different developmental stages showing high levels of Nolz1 protein at embryonic stages, which decrease during postnatal development.
Within adult mice, Nolz1 expression remains at low levels in the striatum (Str) but is not detectable in the subependymal zone (SEZ). (B) In situ
hybridization shows high levels of Nolz1 mRNA in the SVZ of the E14.5 vLGE. Note that the levels of Nolz1 mRNA decrease in the mantle zone
(MZ). Scale bars: 600 μm. (C) Low levels of Nolz1 mRNA are also detected in the adult striatum but not in the subependymal zone. Scale bar:
150 μm. (D) Double in situ immunohistochemistry shows that within the MZ, Nolz1 expression is located in b-III tubulin (Tuj-1)-positive cells.
Scale bar: 150 μm. (E) High magnification of (D). Scale bar: 60 μm.
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promotes cell cycle exit. Next, we studied the capacity of
NPCs to form new neurospheres 5 DIV after hNolz
over-expression or transfection of Nolz1 siRNA (Figure
4F). hNolz negatively regulated NPC self-renewal, as
shown by the decrease in the number of new neuro-
spheres formed after hNolz over-expression and the cor-
responding increase observed after Nolz1 siRNA
transfection (Figure 4E, P0). When cells were dissociated
and plated again (P1), no differences were observed in
any condition studied (Figure 4E). These findings indi-
cate a transient effect of Nolz1 and that variation of the
levels of this transcription factor does not permanently
affect NPC populations since hNolz over-expression or
Nolz1 siRNA was lost after the first passage.
To further confirm the role of Nolz1 in the regulation of
NPC proliferation, we next electroporated hNolz into
LGE-derived organotypic cultures from E15.5 embryos
and analyzed the number of Ki67-positive cells (Figure 5).
Two days after electroporation, hNolz over-expression
reduced the proliferation of NPCs at the SVZ as indicated
by the dramatic decrease in the number of Ki67-positive
cells with respect to the control electroporated side
(Figure 5B).
Nolz1 over-expression promotes the acquisition of a
neuronal phenotype in LGE primary cultures
Reduced proliferation of NPCs could be indicative of
neural differentiation. To test this possibility, we first
analyzed whether Nolz1 was expressed in differentiated
post-mitotic cells in primary cultures derived from
E14.5 LGEs (Figure 6A,B). Double immunocytochemis-
try against Nolz1 and the neural markers Tuj1 or glial
fibrillary acidic protein (GFAP) showed that most of the
Nolz1-positive cells were positive for the neuronal mar-
ker Tuj1, while we could not find any overlap between
Nolz1 and the astroglial marker GFAP (Figure 6A,B).
We also analyzed the role of Nolz1 on neural differen-
tiation by transfecting LGE primary cultures with
Figure 3 Nolz1 is highly expressed in proliferating NPCs and down-regulated during differentiation. (A) Nolz1 mRNA expression is down-
regulated during NPC differentiation. NPC samples from different stages of differentiation (0, 3 and 6 DIV) were analyzed by RT-PCR to study the
expression pattern of Nolz1. The results are expressed as the percentage of the expression levels at 0 DIV, considered as 100%, and represent the
mean from at least three independent samples at each condition. Error bars represent the standard error of the mean. Statistical analysis was
performed with one-way ANOVA, followed by the Bonferroni post-hoc test. **P < 0.01, ***P < 0.001 relative to 0 DIV. (B) Nolz1 fluorescent
immunocytochemistry was performed on NPC samples at different stages of differentiation (0, 3 and 6 DIV). Many Nolz1-positive cells were
detected in proliferating neurospheres while the intensity and number of positive cells clearly decreased during differentiation. Scale bar: 50 μm.
Urbán et al. Neural Development 2010, 5:21
http://www.neuraldevelopment.com/content/5/1/21
Page 5 of 22
Figure 4 Nolz1 regulates proliferation and self-renewal of NPCs. (A) hNolz over-expression produces a down-regulation of endogenous
mouse Nolz1 (mNolz1) at 2 and 5 DIV after transfection with hNolz1-DsRED. Values are expressed as the mean percentage of control transfection
(DsRED alone), considered as 100%. (B) Western blot of NPC protein extracts 5 DIV after transfection with DsRED control (Cont.) or hNolz-DsRED
(hNolz), showing an increase in Nolz after hNolz transfection. (C) Western blot of NPC protein extracts 2 DIV after transfection of Nolz1 small
interfering RNA (siRNA) or control siRNA. The expression of Nolz1 decreases about 82% in the cultures transfected with the Nolz1 siRNA relative
to those transfected with the control siRNA. (D,E) Over-expression of hNolz in NPCs reduces the number of bromodeoxyuridine (BrdU)-positive
cells, whereas Nolz1 siRNA transfection causes an increase in the number of BrdU-positive cells. Results are expressed as the relative number of
BrdU-positive cells, standardized to their respective control, considered 100% (dotted line). (F) Nolz1 over-expression results in a decrease in
neurosphere generation, while Nolz1 silencing results in an increase in the number of neurospheres just after transfection (P0, passage 0). When
cells are dissociated and plated again (P1, passage 1), no differences were observed in any condition. Results are expressed as the percentage of
counted neurospheres with respect to their respective control, considered 100% (dotted line). (G) Cell-cycle exit index was analyzed as the
percentage of BrdU+/Ki67- cells with respect to the total number of BrdU-positive cells after a 3-DIV pulse label. hNolz induces a significant
increase in the number of cells that leave the cell-cycle with respect to enhanced green fluorescent protein (EGFP)-over-expressing cells. The
results in each graph represent the mean ± standard error of the mean from at least three independent samples at each condition. Statistical
analysis was performed with the Student’s t-test. *P < 0.05, ***P < 0.001 relative to the respective controls.
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plasmids that express hNolz-EGFP or EGFP alone as
control (Figure 6C,D). Five days after transfection, we
performed double immunocytochemistry for GFP and
the neural precursor gene nestin, the neuronal markers
Tuj1 and microtubule-associated protein (MAP)2 or the
astroglial marker GFAP. hNolz-over-expressing cells
mainly colocalized with the neuronal markers Tuj1 and
MAP2, although some double GFP-nestin stained cells
were also observed (Figure 6C). In contrast, no astroglial
cell markers were seen in hNolz transfected cells, as
shown by the lack of colocalization between GFP and
GFAP (Figure 6C). Interestingly, the quantification of
the double positive cells in hNolz (hNolz-EGFP) versus
control transfected cells (EGFP) demonstrated that
hNolz promotes a neuronal phenotype (Figure 6D).
hNolz over-expression increased the number of both
Tuj1- and MAP2-positive neurons, which was accompa-
nied by a reduction in the number of nestin-positive
cells (Figure 6D). In addition, no hNolz-over-expressing
cells were GFAP-positive astroglia (Figure 6D).
Nolz1 expression is downstream of Gsx2 and its levels are
temporarily regulated by RA during striatal development
To determine whether RA is needed for Nolz1 expres-
sion in striatal cells during development, pregnant mice
were fed with a vitamin A (retinol)-deficient diet, which
results in a general decrease of RA blood levels [31]. In
these animals the levels of RARb were partially reduced
(Figure 7A), indicating a decrease in RA levels since it is
well known that this receptor is regulated by RA signals.
Analysis of Nolz1 expression in E14.5 embryos devel-
oped under these vitamin A-deficient levels did not
show any difference with respect to expression in regu-
lar fed wild-type control embryos (Figure 7B,C). To
further confirm that the lack of RA does not affect
Nolz1 expression, we analyzed the levels of Nolz1
expression in Raldh3-/- embryos (Figure 7D), which have
completely lost RA activity [11]. Nolz1 expression was
not affected by the absence of Raldh3 in the LGE at
E14.5 (Figure 7D), further corroborating the indepen-
dence of Nolz1 expression from RA signaling in the
vLGE at this developmental stage.
To analyze whether Nolz1 expression levels were regu-
lated by RA in vitro, LGE-derived neurospheres were
treated with increasing concentrations of RA during 3
DIV and the levels of Nolz1 were analyzed by quantita-
tive PCR (Q-PCR). Nolz1 expression was increased by
RA in E12.5-derived NPC cultures (Figure 8A). How-
ever, it was not affected in E14.5-derived NPC cultures
(Figure 8C). As a well known RA-induced control gene,
we analyzed RARb, which was clearly upregulated in a
dose-dependent manner at both stages (Figure 8B,D).
Coincidentally, Nolz1 expression did not change in
E14.5 LGE primary cultures treated with RA, although
Figure 5 Nolz decreases NPC proliferation in the SVZ of LGE
organotypic cultures. (A) Organotypic cultures from E15.5 LGE
were electroporated in the VZ/SVZ with hNolz (hNolz-DsRED) or the
control vector (DsRED) and stained for Ki67 (white arrows indicate
the fluorescent DsRED-expressing cells). Over-expression of hNolz
produces a reduction in cell proliferation in the SVZ as shown by
the reduction in Ki67-positive cells in the electroporated area. Scale
bar: 600 μm. (B) High magnification of the electroporated area
showing the decrease in Ki67-positive cells in the SVZ of the LGE.
Scale bar: 300 μm. (C) Quantification of the number of Ki67-positive
cells in the transfected area. The results represent the mean ±
standard error of the mean from four independent experiments.
Statistical analysis was performed with the Student’s t-test; *P < 0.05.
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Figure 6 Nolz1 acts as a neurogenic factor in primary LGE cultures. (A,B) Double fluorescent immunocytochemistry performed on primary
E14.5 LGE cultures. Nolz1 is expressed in cells positive for the early neuronal marker Tuj1 (A). In contrast, Nolz1 is not detected in cells
expressing the astroglial marker glial fibrillary acidic protein (GFAP) (B). White arrows show double positive cells, open arrows show single stained
cells for Tuj1 or GFAP, and white arrowheads show single stained cells for Nolz1. Scale bar: 50 μm. (C,D) Over-expression of hNolz in LGE primary
cultures increased the number of neurons at the expense of glial fates as shown by the increase in the number of Tuj1- or MAP2-positive cells
and the complete blockade of astroglial cells. Note that all cells over-expressing hNolz are negative for the GFAP marker (C). (C) White arrows
show single stained cells for Nolz1, white arrowheads show double positive cells and open arrows show single GFAP-positive cells. Scale bar: 50
μm. (D) The results represent the mean ± standard error of the mean from at least three independent samples at each condition. Statistical
analysis was performed with the Student’s t-test. *P < 0.05, ***P < 0.001 relative to EGFP control.
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RARb was also increased in these cultures (Figure 8E).
Therefore, striatal cultures were competent to increase
Nolz1 expression in response to RA treatment at E12.5
but not at later stages. In agreement with these results,
when we treated mouse embryonic stem cells with RA,
Nolz1 expression was upregulated in a dose-dependent
manner (Figure 9), supporting that Nolz1 competence to
RA signaling depends on early developmental stages.
Since Gsx2 is essential for the correct expression of
several RA-dependent genes, such as Raldh3, in the
LGE [18], we also examined the expression of Nolz1 in
Gsx2 knockout mice. Nolz1 expression was analyzed by
in situ hybridization in knockout mice carrying a single
(Gsx2+/EGFP) or double substitution of the Gsx2 gene for
EGFP (Gsx2EGFP/EGFP) [32]. Low levels of Nolz1 expres-
sion remained in the Gsx2 heterozygous mouse vLGE at
E14.5 (Figure 10A,B), but no signal was detected in the
Gsx2EGFP/EGFP mice (Figure 10C), indicating that Gsx2 is
critical for Nolz1 expression. On the other hand, over-
expression of Gsx2 in NPCs did not lead to an increase
in Nolz1 mRNA levels, while it enhanced the levels of
Raldh3 mRNA (Figure 10D), which has been shown to
be regulated by Gsx2 [18]. These findings indicate that
Gsx2 is essential but not sufficient to induce Nolz1
expression.
RA signaling is necessary to induce Nolz1-dependent
neurogenesis
The specific combination of RA receptors defines the
competence of cells to respond to RA. Thus, we next
analyzed whether Nolz1 expression regulates RARs. We
measured RARa, RARb and RARg mRNA levels 2 and 5
DIV after hNolz over-expression or silencing with Nolz1
siRNA in NPCs (Figure 11A). We did not detect RARg
expression in control NPCs, or after transfection of
hNolz or Nolz1 siRNA (data not shown). In contrast,
both RARa and RARb were highly expressed in NPCs.
RARa levels were not modified in any condition studied
whereas RARb levels were increased 5 DIV after hNolz
over-expression and reduced after Nolz1 silencing
(Figure 11A). In addition, hNolz over-expression did not
regulate the level of Raldh3 mRNA (Figure 11A). Simi-
larly, the levels of CRBP1 and Cyp26, two other limiting
proteins for RA metabolism, were not modified by
hNolz overexpression (data not shown). These findings
indicate that Nolz1 expression does not increase RA
levels but changes the competence of cells to respond to
RA. To further test this hypothesis, we analyzed whether
hNolz over-expression could activate RA signaling using
a Luciferase RARE-reporter assay. Three DIV after
transfection, an increase in luciferase activity was
observed (Figure 11B), demonstrating that this transcrip-
tion factor leads to an increase in RA signaling. These
results suggested that Nolz1 could induce the conversion
Figure 7 Nolz1 expression does not depend on RA signaling in
the LGE in vivo. (A) Embryos developed under a vitamin A-
deficient diet (vVitamin A -) had reduced levels of RARb expression
compared to wild-type control mice (WT Control). Values are
normalized to control (regular diet), considered as 100%, and
expressed as the mean of four independent samples for each
condition. Error bars represent the standard error of the mean.
Statistical analysis was performed with the Student’s t-test. **P <
0.01 relative to control. (B) In situ hybridization for Nolz1 performed
in regular fed wild-type E14.5 embryos. (C) In situ hybridization at
E14.5 shows normal Nolz1 expression levels. (D) Similarly, Raldh3-/-
embryos at E14.5 show normal Nolz1 expression. Scale bars: 600 μm.
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of NPCs into neuronal cells through the regulation of
RARb-mediated signaling. Thus, we next analyzed
whether Nolz1 mediates NPC cell cycle exit and pro-
motes neuronal differentiation by this mechanism.
Surprisingly, RA signaling does not seem to mediate
Nolz1-regulated proliferation of NPCs, since under the
same conditions that hNolz modified BrdU incorpora-
tion, treatment with RA (Figure 12A) or a RARb-specific
agonist (Figure 12B) did not affect neurosphere prolif-
eration (Figure 12). Thus, we next analyzed whether RA
signaling was necessary for Nolz1-induced neurogenesis.
To this end, we transfected primary striatal cultures
Figure 8 Striatal cultures are temporarily competent to regulate Nolz1 expression in response to RA. NPC and primary cultures were
treated with RA and the expression of Nolz1 and RARb were analyzed by Q-PCR. (A,B) RA increases the expression of Nolz1 and RARb in a dose-
dependent manner (0, 10-9, 10-8 and 10-6 M) in E12.5-derived neurospheres. (C,D) Within E14.5-derived neurospheres, RA increases the expression
of RARb in a dose-dependent manner (D) but it does not affect Nolz1 mRNA levels (C). (E) RA increases the levels of RARb without affecting
Nolz1 mRNA levels in LGE primary cultures treated with 10-8 M RA during 3 DIV. The results represent the mean ± standard error of the mean
from at least three independent samples at each condition. Statistical analysis was performed with one-way ANOVA, followed by the Bonferroni
post-hoc test (A-D) or with the Student’s t-test (E). *P < 0.05, **P < 0.01, ***P < 0.001 relative to control.
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with hNolz in the absence of RA, since cells were cul-
tured in a RA-free medium supplemented with 4-diethy-
laminobenzaldehyde (DEAB), a Raldh inhibitor [33].
Under these conditions, the levels of RARb and Raldh3
were highly reduced (Figure 13A). Moreover, hNolz
could not induce neuronal differentiation in the absence
of RA, since hNolz-induced neurogenesis was lost in the
presence of DEAB (Figure 13B,C). To further study
whether the effect of Nolz1 in neurogenesis was not
only dependent on RA but also on RARb signaling, we
next over-expressed hNolz in striatal primary cultures
treated with a pan-RAR inverse agonist (BMS493, also
named UVI2024, [34,35]). In these conditions, hNolz
was also unable to induce an increase of Tuj1-positive
cells and a reduction of nestin-positive precursors or
GFAP-positive astroglia (Figure 14). Therefore, these
results demonstrate that Nolz1 needs RA signaling
through RARs to mediate striatal neurogenesis. How-
ever, the stimulation of RARb with a specific agonist
(BMS641, also named UVI2003, [36]) was not sufficient
to induce changes in neural markers in striatal cultures
(Figure 15).
Tle4 and Nolz1 have parallel expression patterns in both
the LGE in vivo and LGE-derived NPCs
Due to the ability of the NET family of transcription
factors, which includes Nolz1, to bind to members of
the Gro-TLE family of transcriptional repressors
Figure 9 Nolz1 expression is induced by RA in embryoid
bodies derived from mouse embryonic stem cells. Embryoid
bodies were treated with various concentrations of RA (0, 10-9, 10-8
and 10-6 M) and 4 DIV later Nolz1 expression levels were analyzed
by Q-PCR. Values are normalized to control (without RA), considered
as 100%, and expressed as the mean from at least three
independent samples at each stage studied. Error bars represent the
standard error of the mean. Statistical analysis was performed with
one-way ANOVA, followed by the Bonferroni post-hoc test. **P <
0.01 relative to control.
Figure 10 Gsx2 is a permissive factor for Nolz1 expression.
(A-C) Nolz1 mRNA expression is detected in E14.5 wild-type mice
(Gsx2+/+; A) and Gsx2+/EGFP mice (B), but totally disappears in the
vLGE of Gsx2EGFP/EGFP mice (C). Scale bars: 600 μm. (D) Gsx2 over-
expression in NPCs does not modify Nolz1 mRNA levels, although it
increases Raldh3 mRNA expression. The results represent the mean
± standard error of the mean from at least three independent
samples at each condition. Statistical analysis was performed with
the Student’s t-test. *P < 0.05, relative to control.
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[22,20,24], we analyzed the expression of several mem-
bers of the Gro-TLE family in the LGE at E14.5 by in
situ hybridization (Figure 16). We did not detect any
Tle2 expression, and Tle3 mRNA was slightly but
broadly expressed through the telencephalon (Figure
16A). Tle1 and Tle4, in contrast, were specifically regu-
lated in the different proliferative zones of the LGE (Fig-
ure 16A). Tle1 expression was maximal in the VZ, and
decreased in the SVZ and MZ (Figure 16A). In contrast,
Tle4 was not expressed in the VZ and its levels were
high in the SVZ, extending to the MZ but at lower
expression levels (Figure 16A), thus resembling the
expression pattern of Nolz1 (Figure 2). To determine if
Nolz1 and Tle4 were co-expressed in the LGE, we per-
formed in situ hybridization for Nolz1 followed by
immunohistochemistry for Tle4, which confirmed their
colocalization within the LGE (Figure 16B). We also
analyzed the Tle4 expression pattern during NPC differ-
entiation. Tle4 followed a pattern of expression similar
to that of Nolz1, as its maximal levels were achieved in
non-differentiated NPCs and decreased with differentia-
tion (Figure 16C).
Discussion
Our results show that Nolz1 expression is high in the
SVZ and is maintained at low levels in the MZ of the
LGE, suggesting a dual effect promoting cell cycle exit
and neuronal differentiation of NPCs. We found that
Nolz1 expression negatively regulates the proliferation
and induces cell cycle exit of NPCs cultured as neuro-
spheres. In addition, in LGE-derived primary neural cul-
tures, Nolz1 over-expression increased the number of
Figure 11 Nolz1 increases RARb expression and induces RA
signaling. (A) RT-PCR analysis of RARa, RARb and Raldh3 mRNA at
2 and 5 DIV after transfection of hNolz (hNolz over-expression) or
Nolz1 siRNA. The results are expressed as the mean ± standard error
of the mean from at least three independent samples for each
condition, and normalized to the respective control transfection
(DsREd or control siRNA), considered as 100% (dotted line). (B) RARE
luciferase reporter assay demonstrates that Nolz1 over-expression
increases RA signaling in primary striatal cultures. The results are
expressed as the mean ± standard error of the mean from four
independent experiments, and normalized to the respective control
transfection (EGFP), considered as 100%. *P < 0.05, **P < 0.01,
relative to control.
Figure 12 RA does not affect the proliferation of NPCs in
culture. (A) NPCs grown as neurospheres were treated with various
concentrations of RA (0, 10-9, 10-8 and 10-6 M) and after 3 DIV the
number of BrdU-positive cells was analyzed. RA treatment did not
have any effect on NPC proliferation at any of the concentrations
studied. (B) The same result was observed when NPC cultures were
treated with a RARb-specific agonist (10-8 M). Values are normalized
to control (not treated with RA or RARb agonist), considered as
100%, and expressed as the mean ± standard error of the mean
from at least three independent samples for each condition.
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neurons at the expense of nestin- and GFAP-positive
cells, indicating that Nolz1 participates in striatal neuro-
genesis. We also show that Nolz1-induced neurogenesis
depends on RA signaling, since this transcription factor
promoted the expression of RARb in LGE-derived NPCs
and its neurogenic effect was impaired in a RA-signal-
ing-free context.
The shape of the telencephalon and the relative sizes
and positions of its cell populations result from
Figure 13 Nolz1-mediated neurogenesis depends on RA
signaling. (A) RT-PCR analysis of RARa, RARb and Raldh3 mRNA
expression in NPC cultures grown in normal conditions (control), in
vitamin A-free medium (VitA-) and in vitamin A-free medium in the
presence or DEAB (VitA- & DEAB) demonstrates a decrease in RARb
and Raldh3 mRNA in the absence of RA. The results are expressed
as the mean ± standard error of the mean from at least three
independent samples for each condition, and normalized to the
control medium, considered as 100%. Statistical analysis was
performed with the Student’s t-test. ***P < 0.001 relative to control.
(B,C) Nolz1 does not induce neuronal differentiation in a RA-free
environment. (B) Representative pictures of immunofluorescence for
Tuj1 or GFAP after transfection of hNolz in the absence or presence
of DEAB. White arrows show double positive cells, open arrows
show single EGFP stained cells. Scale bar: 30 μm. (C) Treatment with
1 μM DEAB in a vitamin A-free medium (DEAB) impairs the increase
of Tuj1 and the reduction of GFAP observed in hNolz-transfected
primary striatal cultures in control conditions (Cont.). The results are
expressed as the mean ± standard error of the mean from at least
three independent samples for each condition, and normalized to
the control medium, considered as 100%. Statistical analysis was
performed with the Student’s t-test (C). **P < 0.01, ***P < 0.001
relative to control. N.s., not significant.
Figure 14 RAR activity is essential for Nolz1-mediated
neurogenesis. (A,B) Nolz1 does not induce neuronal differentiation
in the presence of a RAR inverse agonist. (A) Representative pictures
of immunofluorescence for Tuj1 or GFAP after transfection of hNolz
in the absence or presence of a RAR inverse agonist (BMS493).
White arrows show double positive cells, open arrows show single
EGFP stained cells. Scale bar: 30 μm. (B) The presence of the RAR
inverse agonist (10-8 M BMS493) impairs the increase of Tuj1 and
the reduction of GFAP observed after hNolz transfection in primary
striatal cultures (Cont.). The results are expressed as the mean ±
standard error of the mean from at least three independent
samples for each condition, and normalized to the transfection in
standard culture conditions (Cont.), considered as 100%. Statistical
analysis was performed with the Student’s t-test. **P < 0.01, ***P <
0.001 relative to control.
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variations in cell proliferation [37] and many transcrip-
tion factors have important roles in this mechanism.
Our results show that Nolz1 contributes to the homeo-
stasis of NPCs in the SVZ of the vLGE, where it is
highly expressed ([19] and our present results), by redu-
cing the proliferation, promoting cell cycle exit and pos-
sibly reducing the self-renewal potential of NPCs. Cell
cycle exit during LGE embryonic development is usually
associated with proneural transcription factors. Here we
demonstrate that Nolz1 promotes the acquisition of a
neuronal phenotype since over-expression of Nolz1 in
LGE primary cultures produces an increase in the num-
ber of neurons. Proneural factors such as Ascl I (also
known as Mash1) [32] are restricted to the VZ and
SVZ, where progenitors begin to differentiate, but are
absent in the MZ, where fully differentiated neurons are
found. However, other transcription factors such as
Meis2 or Islet are expressed in both the germinal VZ
and SVZ and in the MZ [28,38]. Similarly, Nolz1 expres-
sion is high in the SVZ and its expression decreases but
does not disappear in the MZ, where striatal neurons
continue to express low levels of Nolz1 ([19] and pre-
sent results). These results agree with the idea that
stable specification of cell identity requires mechanisms
that maintain patterns of gene expression over long per-
iods of time [39].
One of the main issues in cell fate specification is the
understanding of the interaction between two general
sets of determinative factors: secreted extrinsic signals
present in a cell’s local environment and intrinsic signals
that operate in a cell-autonomous manner [39]. Keeping
with this view, RA signaling can increase Nolz1 levels in
the PC12 cell line [19] and in chick postmitotic moto-
neurons [20]. Our results demonstrate that Nolz1
expression was not modified when a vitamin A-deficient
diet was used to feed the mothers, which results in low-
ered levels of RA synthesis in the pups throughout the
whole of development [31]. In addition, Nolz1 expres-
sion was not affected in Raldh3-deficient animals, which
have been shown to lack RA activity in the LGE [11].
These findings suggest that the levels of RA are not lim-
iting for Nolz1 expression. Reinforcing this idea, we
observed that RA does not regulate Nolz1 expression in
E14.5-derived NPCs or primary cultures. However,
E12.5-derived NPCs do respond to RA by increasing the
expression of Nolz1. Similarly, RA was able to regulate
Nolz1 in mouse embryonic stem cells. Altogether, these
data indicate that the ability of cells to induce Nolz1 in
response to RA is dynamically regulated during striatal
development. Thus, a very interesting possibility is that
RA participates in the induction but not in the mainte-
nance of Nolz1 expression, since other sources of RA in
the LGE has been described [40].
Interestingly, we found that Gsx2 is required for the
correct expression of Nolz1 in the vLGE, the mouse tel-
encephalic structure that gives rise to striatal projection
neurons (for a review, see [41]). In agreement with this
result, it has recently been shown that Gsx2 participates
in the temporal specification of neuronal fate in the
LGE [42]. The development of striatal projection neu-
rons depends on early actions of Gsx2 during differen-
tiation of the vLGE, where Nolz1 is expressed, while
differentiation of the dLGE, where Nolz1 is not
expressed, requires Gsx2 function at least until birth
[42]. However, over-expression of Gsx2 in NPCs did not
modify the levels of Nolz1, suggesting that Gsx2 acts as
a permissive instead of an inductive factor for Nolz1
expression. Since Gsx2 is involved in the differentiation
of striatal projecting neurons through the regulation of
RA signaling [18], Nolz1 could act downstream of Gsx2
to regulate RA signaling. We found that Nolz1 regulates
the expression of RARb, the RA receptor that has been
shown to promote striatal projection neuron differentia-
tion [12,15,43]. In addition, early striatal neurogenesis is
affected in RARb mutant mice [44], coinciding with the
expression and function of Nolz1. In fact, Nolz1 and
RARb are expressed in the MZ at the same developmen-
tal stages ([19,45] and present results). Furthermore, our
present results demonstrate that Nolz1 induces not only
increases in RARb but also RA signaling, which is essen-
tial to exert its neurogenic effect in primary striatal cul-
tures. Interestingly, although this receptor is necessary
for Nolz1-induced neurogenesis, its activation by a
Figure 15 RARb stimulation is not sufficient to induce
neurogenesis in primary striatal cultures. RT-PCR analyses of
neural markers in primary striatal cultures treated with an RARb
agonist (10-8 M; BMS641) demonstrate that it does not modify
striatal neurogenesis. The results are expressed as the mean ±
standard error of the mean from at least three independent
samples for each condition, and normalized to the control medium
without the RARb agonist, considered as 100%. Statistical analysis
was performed with the Student’s t-test.
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Figure 16 Tle4 and Nolz1 expression show similar patterns in the developing LGE and in NPCs. (A) In situ hybridization study to analyze
Tle1, Tle2, Tle3 and Tle4 mRNA levels in the LGE at E14.5. Dashed lines mark the VZ-SVZ boundary. (B) Simultaneous Tle4 immunohistochemistry
and Nolz1 in situ hybridization show coincident expression patterns in the LGE at E14.5. (C) High levels of Tle4 mRNA are observed in
proliferating NPCs (0 DIV), which decrease after differentiation (3 and 6 DIV). The results are expressed as the mean from at least three
independent samples for each condition, and normalized to the proliferating NPCs (0 DIV), considered as 100%. Error bars represent the standard
error of the mean. Statistical analysis was performed with one-way ANOVA, followed by the Bonferroni post-hoc test. **P < 0.01 relative to
control. Scale bars: 600 μm (A); 100 μm (B).
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selective RARb agonist is not sufficient to stimulate any
changes in neural markers. This result suggests that
Nolz1 may also act on additional pathways to promote
neural differentiation. Altogether, these findings show
that Nolz1 participates in the early Gsx2-dependent dif-
ferentiation of vLGE-derived neurons through the regu-
lation of RARb-mediated signaling.
It has been shown that Gsx2 mutant mice have
reduced levels of Raldh3 [18]. In addition, we show that
over-expression of Gsx2 in NPCs increases the mRNA
levels of this striatal RA-limiting enzyme. However, we
observed that Nolz1 did not regulate the expression of
Raldh3, so it is not regulating RA synthesis. These
results suggest that Gsx2 may regulate RA signaling at
two different levels; one is Nolz-independent and
mediated by the regulation of Raldh3 and the other
involves the regulation of Nolz1 expression, which in
turn regulates the levels of RARb.
RARb is expressed in the MZ while RARa is broadly
expressed in the VZ and SVZ through the entire tele-
ncephalon and is important in the control of the prolif-
eration of neural precursors [11,46]. We observed that
RARa is unaffected by Nolz1 over-expression. Thus, it
seems that Nolz1 acts through RA signaling to regulate
the differentiation of striatal projection neurons but its
effect on NPC proliferation is independent of RA. In
fact, we observed that RA did not modify the prolifera-
tion of NPCs in vitro. Increases in cell cycle length
could lead to progressive restriction of the proliferation
potential of LGE NPCs, and it can be promoted by tran-
scription factors such as Foxg1 [37]. However, Nolz1 did
not induce changes in cell cycle length. Another inter-
esting possibility is that Nolz1 and Gsx2 function
together to regulate proliferation since Gsx2 expression
in the SVZ coincides with Nolz1 ([19,32] and present
results). Keeping with this view, it has been shown that
the Gsx2 homolog in Drosophila, Ind (intermediate neu-
roblasts defective), interacts with Gro proteins, which
are able to bind elB (elbow B), the Nolz1 homolog, act-
ing as transcriptional co-repressors [27]. In addition, the
mammalian Nolz1 protein also contains the conserved
FKPY sequence, which allows binding to Gro-TLE pro-
teins (Figure 1A). We observed that many TLE (NocA-
elB-Tlp) proteins, the mammalian homologs of Gro, are
expressed in the vLGE. Among them, TLE4 follows a
similar expression pattern to Nolz1, with its highest
levels in the SVZ, while the VZ is enriched in TLE1
expression. These results are similar to those observed
in the cerebral cortex, where TLE4 is expressed by more
differentiated NPCs of the SVZ and TLE1 expression is
elevated in the undifferentiated VZ neural precursors
[47-49]. Moreover, TLE4 expression decreased upon
NPC differentiation. Taken together, these findings sug-
gest that Nolz1 and TLE4 could act together to control
SVZ proliferation in the LGE. Similarly, it has been
recently described that Nolz1 requires, in part, the mod-
ulatory activity of Grg5, an atypical member of the Gro-
TLE family of co-repressors, to control motor neuron
determination in the chick spinal cord [20]. However,
further experiments are required to analyze functional
interactions between these proteins.
In conclusion, we demonstrate that Nolz1 has a dual
effect on NPCs, on one hand by controlling their prolif-
eration and promoting cell cycle exit, and on the other
by inducing striatal neurogenesis. Nolz1 over-expression
increases the number of striatal neurons downstream of
Gsx2 by inducing RA signaling through RARs. Its prop-
erties and expression pattern suggest that the activity of
Nolz1 in the vLGE could be modulated by co-repres-
sors, such as Gro-TLE.
Materials and methods
Animal subjects
All animals were housed with access to food and water
ad libitum in a colony room maintained at a constant
temperature (19 to 22°C) and humidity (40 to 50%) on a
12:12 h light:dark cycle. Animal treatments and handling
procedures were approved by the Local Committees, in
accordance with the European Community Council
Directive (86/609/EU).
B6CBA wild-type mice (from Charles River Labora-
tories, Les Oncins, France), Raldh3-deficient mice [11],
and Gsx2-deficient mice [32] were used in this study.
For embryonic ages, time of pregnancy was determined
by first detection of a vaginal sperm plug by daily
inspection and considered as E0.5. For postnatal studies,
the day of birth was considered as postnatal day 0 (P0).
To induce vitamin A deficiency in mice, pregnant
mice were fed with the vitamin A-deficient diet
TD.86143 (Harlan Laboratories Inc., Indianapolis, IN,
USA).
Culture procedures
E12.5 or E14.5 fetal brains were excised and placed in
sterile phosphate-buffered saline pH 7.4, and the LGEs
were dissected bilaterally, pooled and gently dissociated
with a fire-polished Pasteur pipette.
Mixed neuron-glial primary cultures were obtained by
plating the cells onto 24-well plates containing glass
coverslips precoated with 0.1 mg/ml poly-D-lysine
(Sigma Chemical Co., St Louis, MO, USA) at a density
of 150,000 cells/cm2 in Eagle’s minimum essential med-
ium (Invitrogen SA, Prat de Llobregat, Barcelona, Spain)
supplemented with 7.5% fetal bovine serum (FBS; Invi-
trogen SA), 0.6% D-(+)-glucose (Sigma Chemical Co.),
100 U/mL of penicillin and 100 mg/mL streptomycin
(both obtained from Invitrogen SA). Three or 5 days
after seeding, cultures were fixed with 4%
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paraformaldehyde solution (PFA; Merck Biosciences Ltd,
Nottingham, UK) in 0.1 M phosphate buffer pH 7.4 and
processed for immunocytochemistry.
LGE-derived neurosphere cultures were obtained by
seeding 50,000 cells/cm2 in medium containing Dubelc-
co’s Modified Eagle’s Medium (DMEM; Sigma Chemical
Co.):F12 (Invitrogen SA) (1:1); supplemented with 0.3%
glucose (Sigma Chemical Co.), 0.3 mg/ml glutamine
(Invitrogen SA), 5 mM HEPES (Invitrogen SA), 100 U/
ml penicillin, and 100 mg/ml streptomycin (Invitrogen
SA), 4 μg/ml heparin (Sigma Chemical Co.), 4 mg/ml
bovine serum albumin (Sigma Chemical Co.), 1× N2
supplement (Invitrogen SA), 20 ng/ml fibroblast growth
factor (Sigma Chemical Co.) and 10 ng/ml epidermal
growth factor (Invitrogen SA). Every 5 days neuro-
spheres were collected, dissociated by pipetting approxi-
mately 40 times with a P100 micropipette and re-plated
in fresh media at a density of 10,000 cells/cm2.
For cell differentiation, 12,500 cells/cm2 were seeded.
The day after plating, cells were collected and incubated
onto Matrigel-treated coverslips (Growth Factor
Reduced Matrigel Matrix, BD Biosciences, Clontech-
Takara Bio Europe, Saint-Germain-en-Laye, France).
Media was changed to medium supplemented with only
20 ng/ml fibroblast growth factor (Sigma Chemical Co.)
and cells were allowed to differentiate in this medium
for 2 more days. Then, media was changed again to
medium supplemented with 2% FBS (Invitrogen SA)
and cells were grown for 3 more days (until a total of
6 days of in vitro differentiation). Cell pellets for each
time point (0, 3 and 6 days of differentiation) were
obtained and frozen at -80°C for RNA or protein
extraction.
In the present study, we used the mouse embryonic
stem cell line R1 obtained from Dr Andras Nagy’s
laboratory. The maintenance of undifferentiated mouse
embryonic stemcells, embryoid body formation and cul-
ture were carried out as previously described [15].
All cell cultures were incubated at 37°C in a 5% CO2
atmosphere.
RA and RARb agonist treatment
Neurospheres were passaged as described above and sin-
gle cells were seeded in 6-well plates at a density of 100
cells/mm2 with fresh culture medium containing differ-
ent concentrations of all-trans-RA (10-9, 10-8 and 10-6 M;
Sigma Chemical Co.) dissolved in dimethyl sulfoxide
(DMSO; Sigma Chemical Co.). Control cells were cul-
tured with the same dilutions of the RA vehicle, DMSO.
Some cultures were treated with a RARb-specific agonist
[36] at a concentration of 10-8 M dissolved in DMSO,
which we observed is effective in these cultures (R Mar-
tín-Ibáñez et al., in preparation). NPCs were allowed
to grow for 3 DIV and then were pelleted for RNA
extraction and RT-PCR analysis or processed for BrdU
immunocytochemistry.
Mixed neuron-glial LGE primary cultures were grown
for 3 DIV and RA or RARb agonist (BMS641) dissolved
in DMSO was added to the medium at the concentra-
tion of 10-8 M. Fresh RA/RARb agonist was added every
24 hours of culture and 3 hours prior to fixation.
Embryoid bodies were formed as described above and
RA was added to the culture medium at different con-
centrations (10-9, 10-8 and 10-6 M). They were grown
for 4 DIV and then pelleted for RNA extraction and
RT-PCR analysis.
Cell transfection
To over-express NolzI, cells were transfected with the
pNolz-IRES2-DsRED plasmid, that was obtained by clo-
nation of the human NolzI contained in the pOTB plas-
mid (MGC full-length (IRAU) collection, clone ID
4053098) into EcoRI and SmaI restriction sites of p-
IRES2-DsRED-Express plasmid (BD Biosciences) coding
for DsRED fluorescent protein. As a control, we used
pIRES2-DsRED-Express empty plasmid. Tranfection was
made with 9 μg of NolzI-RED or RED plasmid.
To reduce NolzI expression, three different siRNAs
against NolzI mRNA were used (Silencer Pre-designed
siRNAs, IDs 89661, 169777, 89565, Ambion, Applied
Biosystems, Foster City, CA, USA). Tranfection was
made with 2 μM of each siRNA or 6 μM of negative
control siRNA (Silencer Negative Control #1 siRNA,
Ambion).
Low passage (four to seven) embryonic neurospheres
were disaggregated and transfected by nucleofection
following the manufacturer’s protocol (Amaxa Biosys-
tems, Lonza Iberica SA, Barcelona, Spain). Using the
A33 Nucleofector program (Amaxa Biosystems), 5 ×
106 cells were transfected. Viable cells were counted by
trypan blue exclusion in a Neubauer chamber after
nucleofection.
For BrdU incorporation assays, 65,000 cells/cm2 were
seeded after nucleofection. Two days later cells were
collected and incubated for 10 minutes in 24-well plates
with Matrigel-treated coverslips and they were incubated
for 10 minutes in BrdU-containing media at a final con-
centration of 2 μg/ml. Just after incubation, cells were
fixed and processed for immunocytochemistry.
The cell cycle exit index was analyzed as described
elsewhere [30]. Briefly, we performed the same procedure
as for BrdU incorporation except that neurospheres were
pulsed with BrdU the same initial day of inducing hNolz
over-expression and cells were fixed 3 days later. There-
after, neurosphere cultures were processed for BrdU and
Ki67 immunostaining. BrdU-positive but Ki67-negative
cells were counted as the cells that left the cell cycle
during the experimental period.
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In order to analyze cell cycle duration, 10 neuro-
spheres were plated 3 days after transfection in 96-well
plates with complete medium and supplemented with 1
μM BrdU. Neurospheres were attached at 1, 3, 6, 12 and
24 hours after treatment in 96 well-plates pre-coated
with Matrigel. Ten minutes later, cells were fixed in 4%
PFA and processed for immunocytochemistry.
For the self-renewal assay, 65,000 cells/cm2 were
seeded after nucleofection and the total number of neu-
rospheres obtained 5 days later was counted (passage
0 (P0) after transfection). Cells were dissociated and
2,500 cells/cm2 were seeded and counted again on day
5 (passage 1 (P1) after transfection).
For differentiation after nucleofection, 50,000 cells/
cm2 were seeded and the same protocol as for non-
nucleofected cells was followed.
To over-express Nolz1 in primary cultures, we trans-
fected the cells with the pLV-Nolz-IRES-EGFP plasmid
or the pLV-IRES-EGFP plasmid, which encode hNolz
and EGFP or EGFP only, respectively. The pLV-IRES-
EGFP plasmid was generated using the pRRLsinPPT
plasmid (pRRL) constructed by the Miami Project to
Cure Paralysis Viral Vector Core Lab based on the lenti-
viral transducing plasmid developed by Naldini et al.
[50]. Briefly, the multiple cloning site (MCS) of the
pRRL plasmid was substituted by the MCS-IRES-EGFP
from the PRV-IRES-EGFP (Genetrix SL, Tres Cantos,
Madrid, Spain) using the BamHI and the SalI restriction
sites. To construct the pLV-Nolz-IRES-EGFP, the hNolz
gene from the pNolz-IRES2-DsRED plasmid was cloned
into pLV-IRES-EGFP between the MCS BamHI and
XhoI sites. Primary cultures were transfected 24 hours
after seeding with 0.5 μg of the corresponding plasmids
per well (24-well plate). The transfection was performed
using Lipofectamine LTX (Invitrogen SA), following the
manufacturer’s instructions. Three days after transfec-
tion cells were fixed with 4% PFA for immunocytochem-
istry analysis.
For DEAB (Sigma Chemical Co.) treatment, primary
cultures were transfected 12 h after seeding as described
above. Then, 24 h later DEAB was added to the medium
at a concentration of 10-8 M. Three days after treatment
cells were fixed with 4% PFA for immunocytochemistry
analysis.
For RAR inverse agonist administration, primary cul-
tures were transfected 12 h after seeding as described
above. Thereafter, the RAR inverse agonist (BMS493
[35]) was added to the medium at a concentration of
10-8 M in DMSO, which was repeated every single day.
At 3 DIV cells were fixed with 4% PFA for immunocyto-
chemistry analysis.
Production of viral particles and cell transduction
To over-express Gsx2, the human Gsx2 gene from the
pcDNA-hGsx2 plasmid, kindly provided by Dr Peter
Marynen (Université de Leuven, Belgium), was PCR-
cloned into the retroviral vector pRV-IRES-EGFP using
the MCS BamHI and XhoI sites.
For retrovirus production, 293T cells were plated at a
density of approximately 6 × 104 cells per cm2. The fol-
lowing day, cells were transfected by a three-plasmid
system (the pRV-Gsx2-IRES-GFP plasmid, the plasmid
that expresses HIV-1 gag and pol genes, and the plasmid
that expresses vesicular stomatitis virus G) using the cal-
cium phosphate/DNA co-precipitate method. The trans-
fection mixture remained on the cells for 7 h before the
transfection medium was replaced with fresh medium.
The supernatant from vector-producing 293T cells was
recovered every 22 h during 3 days before being har-
vested, passed through a 0.45-μm-pore-size filter to
remove producer cells, and then subjected to two centri-
fugations at 4°C and 22,000 × g for 90 minutes to con-
centrate the virus. The virus-containing pellet was
dissolved in 1% bovine serum albumin. Viral concentrate
(20 μl) from pRV-Gsx2-IRES-EGFP or pRV-IRES-EGFP
was used to transduce 3.5 × 106 dissociated NPCs in a
6-well plate as described previously [51]. Transduced
NPCs were growth as neurospheres as described above
for 5 DIV before being pelleted for RNA extraction.
Generation of the anti-Nolz1 antibody
Anti-Nolz1 polyclonal antibodies were obtained from
the serum of immunized rabbits with a keyhole limpet
hemocyanin (KLH)-conjugated oligopeptide coding for
amino acids 2 to 14 of the Nolz1 sequence (MSTAPSL-
SALRSSKH; Figure 1A). Pre-immune serum was
obtained from the same rabbits before immunization.
Immunolabeling
All immunostaining was performed using the following
antibodies: polyclonal anti-NolzI (1:10,000), monoclonal
anti-GFAP (1:500; Sigma Chemical Co.), monoclonal
anti-Tuj1 (1:500; Sigma Chemical Co.), monoclonal anti-
BrdU (1:50; Dako A/S, Glostrup, Denmark), monoclonal
anti-MAP2 (1:200; Sternberger Monoclonals, Lutherville,
MD, USA), polyclonal anti-nestin (Rat 401; 1:40; Devel-
opmental Studies Hybridoma Bank; The University of
Iowa, Iowa), polyclonal anti-Tle4 (1:200; generous gift
from Dr Stefano Stifani, McGill University), polyclonal
conjugated FITC-GFP (1:200; ABCAM, Cambridge, UK),
polyclonal anti-Ki67 (1:200; Thermo Fisher Scientific
SLU, Alcobendas, Madrid, Spain). For Nolz negative
controls, pre-immunization serum was used at the same
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concentration as NolzI antibody-containing serum. Pre-
parations were counterstained with DAPI to visualize
the nucleus.
No signal was detected in control immunostaining
assays in which the primary antibody was omitted.
In situ hybridization
We analyzed the expression of several genes by radio-
active in situ hybridization as described elsewhere [52].
The following oligonucleotide probes were used: mouse
NolzI - complementary to nucleotides 3,226 to 3,266 of
the NolzI sequence (GenBank accession number
NM_145459); mouse Tle1 - complementary to nucleo-
tides 1,942 to 1,983 of the Tle1 sequence (GenBank
accession number NM_011599); mouse Tle2 - comple-
mentary to nucleotides 1,351 to 1,389 of the Tle2
sequence (GenBank accession number NM_019725);
mouse Tle3 - complementary to nucleotides 3,434 to
3,474 of the Tle3 sequence (GenBank accession number
NM_001083927); mouse Tle4 - complementary to
nucleotides 1,614 to 1,652 of the Tle4 sequence (Gen-
Bank accession number NM_0011600).
Quantitative PCR assays
Expression of several genes was evaluated by Q-PCR
assays performed as previously described [15], using the
following TaqMan® gene expression assays (Applied Bio-
systems): 18S, Hs99999901_s1; nestin, Mm00450205_m1;
b-tubulin III, Mm00727586_s1; GFAP, Mm00546086_m1;
MAP2, Mm00485230_m1; Gsx2, Mm00446650_m1;
mouse NolzI, Mm00520908_m1; Raldh3, Mm0047
4049_m1; RARa, Mm00436264_m1; RARb, Mm0131
9674_m1; RARg, Mm00441083_m1; CRBP1, Mm00
441119_m1; Cyp26b1, Mm00558507_m1; Tle4, Mm011
95160_m1. To specifically recognize hNolz, a customized
Taqman® Assay was designed consisting of the following
primers: forward, CCTCGCCCTCCTCCAAAC; reverse,
GCCCGATTTGGTGTCCTTGT; reporter, TCTCCTCG
GTTGCCTCC. To provide negative controls and exclude
contamination by genomic DNA, the reverse transcriptase
was omitted in the cDNA synthesis step, and the samples
were subjected to the PCR reaction with each TaqMan®
gene expression assay.
Analysis and quantification was performed with the
Comparative Quantitation Analysis program of the
MxPro™ Q-PCR analysis software version 3.0 (Strata-
gene, La Jolla, CA, USA), using the 18S gene expression
as internal loading control. All Q-PCR assays were per-
formed in duplicate and repeated for at least three inde-
pendent experiments. The results were expressed as
relative levels with respect to the expression of the same
gene in the control condition, considered as 100%.
Western blotting
We analyzed the levels of Nolz1 protein in transfected
neurospheres or in the striatum at different develop-
mental stages. Samples (at least n = 3 per time point)
were prepared and processed for western blotting as
described elsewhere [53]. Blots were incubated overnight
at 4°C with anti-NolzI antibody (1:50,000). The second-
ary antibody was a horse radish peroxidase-conjugated
anti-rabbit IgG (1:3,000; Promega Biotech Iberica, SL.,
Madrid, Spain) and the signal was developed using the
ECL western blotting analysis system (GE Healthcare
Europe GMBH, Cerdanyola del Vallès, Barcelona,
Spain).
Cell counts
In order to determine the role of NolzI on the prolifera-
tion of progenitor cells in vitro, we counted the number
of cells that incorporate BrdU. BrdU- and EGFP-positive
(transfected) cells were detected by immunocytochemis-
try and the total number of cells determined by DAPI
counterstaining. For over-expressing experiments the
results were expressed as the percentage of proliferating
cells with respect to the transfected (EGFP-positive)
cells, while for siRNA experiments, the results were
expressed as the percentage of proliferating cells with
respect the total number of cells (n = 5). We also
counted by phase contrast the total number of neuro-
spheres 5 days after hNolz or control transfection.
Cell death was evaluated by counting the number of
apoptotic nuclei stained with DAPI after hNolz over-
expression. The results were expressed as the percentage
of dying cells with respect to transfected (EGFP-positive)
cells (n = 4). Results were normalized with respect to
control-transfected NSCs (considered as 100%).
We estimated the cell cycle time as previously
described [1,29]. Briefly, BrdU was added to neurosphere
cultures during the last 1, 3, 6, 12 and 24 h of culturing.
The number of BrdU-positive cells and the total number
of cells, determined by DAPI counterstained nuclei, in
each neurosphere was counted. The percentage of pro-
liferating cells was calculated for each time point after
BrdU administration. Regression analyses of the active
portion of each BrdU labeling curve were used to esti-
mate cell cycle time assuming that all cells proliferate at
the same rate and that every cell is labeled at the end of
a single cycle [29]. The r2 of this lineal correlation was
used to calculate the cell cycle duration. We counted at
least 30 neurospheres in each condition in 3 transfected
cultures.
We analyzed the cell cycle index as the number of
cells that retain BrdU but leave the cell cycle (Ki67-
negative cells) after a 3-DIV pulse label. Thus, we
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counted the fraction of BrdU+/Ki67- cells and normal-
ized to the total number of BrdU-positive cells in the
culture. Results were expressed as absolute percentages
in each condition.
To determine the effect of Nolz1 on the differentiation
of LGE primary cultures, we counted the number of
cells per coverslip overexpressing hNolz or EGFP that
colocalized with different markers, such as nestin, Tuj1
and MAP2 3 or 5 days after the transfection. The results
are expressed as the percentage of transfected cells colo-
calizing with the different markers with respect to the
total number of transfected cells. Between 50 and 200
transfected cells per coverslip were counted per trans-
fection (n = 3 to 5).
Brain slice electroporation
Coronal brain slices (250 μm) from E14.5 mice embryos
were obtained with a vibratome. Slices were plated onto
culture membranes with minimum essential medium
supplemented with 10% FBS and 50 U/ml penicillin-
streptomycin. After 1 hour in the incubator, media was
changed to Neurobasal supplemented with B27, 1 mM
HEPES, 50 U/ml penicillin-streptomycin and 2 mM L-
glutamine. Two hours later, slices were electroporated
with 8 μg of DsRED-Nolz or DsRED plasmid. After
48 hours in culture, electroporated slices were fixed
during 2 hours with 4% PFA, dehydrated with increasing
ethanol concentrations and stored until processing for
immunohistochemistry.
We counted the number of Ki67-positive cells present
in the electroporated zone of brain slices. First, we took
a picture of the slices showing the RED fluorescence of
the electroporated plasmids prior to fixation. Then, the
slices were immunostained against Ki67 and the number
of positive cells included in the electroporated area for
the control side (DsRED plasmid) or experimental side
(Nolz1-DsRED) were counted. The area to count was
fixed by delineating the electroporated DsRED positive
area in the pre-immunostaining image using ImageJ,
and transferring this area to the Ki67 stained image. At
least four different slices were counted for each
condition.
Luciferase RARE reporter assay
To monitor the RARE activity we used the Cignal RARE
Reporter Assay Kit (SABioscience Corporation, Freder-
ick, MD, USA) following the manufacturer’s instruc-
tions. Mixed neuron-glial LGE primary cultures were
performed as described above and 24 hours after seed-
ing cells were transfected with the inducible RARE-
responsive mixture and the pLV-Nolz-IRES-EGFP or the
pLV-IRES-EGFP plasmids. The transfection was per-
formed using Lipofectamine LTX (Invitrogen SA) fol-
lowing the manufacturer’s instructions. Two days later,
cultures were processed to evaluate luciferase using the
Dual-Luciferase Reporter Assay System (Promega). The
firefly/Renilla luciferase ratio was calculated for each
well, and results are expressed as the mean of four inde-
pendent experiments and normalized with respect to
control-transfected primary cultures (considered as
100%).
Statistical analyses
All results are expressed as the mean of independent
experiments ± standard error of the mean. Results were
analyzed using the Student’s t-test or one-way ANOVA
followed by the Bonferroni post-hoc test.
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